123 related articles for article (PubMed ID: 38546166)
1. Combination of Molecule-Targeted Therapy and Photodynamic Therapy Using Nanoformulated Verteporfin for Effective Uveal Melanoma Treatment.
Song M; Zhu L; Zhang L; Ge X; Cao J; Teng Y; Tian R
Mol Pharm; 2024 May; 21(5):2340-2350. PubMed ID: 38546166
[TBL] [Abstract][Full Text] [Related]
2. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
[TBL] [Abstract][Full Text] [Related]
3. Core-matched nanoassemblies for targeted co-delivery of chemotherapy and photosensitizer to treat drug-resistant cancer.
Jiang D; Xu M; Pei Y; Huang Y; Chen Y; Ma F; Lu H; Chen J
Acta Biomater; 2019 Apr; 88():406-421. PubMed ID: 30763634
[TBL] [Abstract][Full Text] [Related]
4. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
5. Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery.
Quinlan JA; Inglut CT; Srivastava P; Rahman I; Stabile J; Gaitan B; Arnau Del Valle C; Baumiller K; Gaur A; Chiou WA; Karim B; Connolly N; Robey RW; Woodworth GF; Gottesman MM; Huang HC
Adv Sci (Weinh); 2024 May; 11(17):e2302872. PubMed ID: 38445882
[TBL] [Abstract][Full Text] [Related]
6. Construction and Evaluation of a Targeted Hyaluronic Acid Nanoparticle/Photosensitizer Complex for Cancer Photodynamic Therapy.
Gao S; Wang J; Tian R; Wang G; Zhang L; Li Y; Li L; Ma Q; Zhu L
ACS Appl Mater Interfaces; 2017 Sep; 9(38):32509-32519. PubMed ID: 28875691
[TBL] [Abstract][Full Text] [Related]
7. Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.
Hu Z; Rao B; Chen S; Duanmu J
BMC Cancer; 2010 May; 10():235. PubMed ID: 20504328
[TBL] [Abstract][Full Text] [Related]
8. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation.
Samadi AK; Cohen SM; Mukerji R; Chaguturu V; Zhang X; Timmermann BN; Cohen MS; Person EA
Tumour Biol; 2012 Aug; 33(4):1179-89. PubMed ID: 22477711
[TBL] [Abstract][Full Text] [Related]
9. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
10. CD71-Specific Aptamer Conjugated with Monomethyl Auristatin E for the Treatment of Uveal Melanoma.
Zhang H; Jin C; Zhang L; Peng B; Zhang Y; Liu Y; Li L; Ye M; Xiong W; Tan W
ACS Appl Mater Interfaces; 2022 Jan; 14(1):32-40. PubMed ID: 34928139
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery and enhanced uptake of chemo-photodynamic nanomedicine for melanoma treatment.
Huang X; Mu N; Ding Y; Lam HW; Yue L; Gao C; Chen T; Yuan Z; Wang R
Acta Biomater; 2022 Jul; 147():356-365. PubMed ID: 35577046
[TBL] [Abstract][Full Text] [Related]
12. Intracellular glutathione levels affect the outcomes of verteporfin-mediated photodynamic therapy in esophageal cancer cells.
Edano M; Kanda T; Tarumoto R; Hamamoto W; Hasegawa T; Mae Y; Onoyama T; Takata T; Sugihara T; Isomoto H
Photodiagnosis Photodyn Ther; 2022 Dec; 40():103090. PubMed ID: 36031142
[TBL] [Abstract][Full Text] [Related]
13. Construction and evaluation of hyaluronic acid-based copolymers as a targeted chemotherapy drug carrier for cancer therapy.
Tang Y; Chen M; Xie Q; Li L; Zhu L; Ma Q; Gao S
Nanotechnology; 2020 Jul; 31(30):305702. PubMed ID: 32272454
[TBL] [Abstract][Full Text] [Related]
14. Nano-Photosensitizer Directed Targeted Phototherapy Effective Against Oral Cancer in Animal Model.
Yu L; Zhu G; Zhang Z; Xu Z; Peng W; Zeng L; Yu Y; Wang S; Lin Z; Zhang X; Zhou N; Zhang L; Liang L
Int J Nanomedicine; 2023; 18():6185-6198. PubMed ID: 37933297
[TBL] [Abstract][Full Text] [Related]
15. Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation.
Ma YW; Liu YZ; Pan JX
Am J Cancer Res; 2016; 6(12):2816-2830. PubMed ID: 28042502
[TBL] [Abstract][Full Text] [Related]
16. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
[TBL] [Abstract][Full Text] [Related]
17. In-Vitro Use of Verteporfin for Photodynamic Therapy in Glioblastoma.
Jeising S; Geerling G; Guthoff R; Hänggi D; Sabel M; Rapp M; Nickel AC
Photodiagnosis Photodyn Ther; 2022 Dec; 40():103049. PubMed ID: 35932958
[TBL] [Abstract][Full Text] [Related]
18. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.
Brodowska K; Al-Moujahed A; Marmalidou A; Meyer Zu Horste M; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Exp Eye Res; 2014 Jul; 124():67-73. PubMed ID: 24837142
[TBL] [Abstract][Full Text] [Related]
19. Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma.
Zhou J; Liu S; Wang Y; Dai W; Zou H; Wang S; Zhang J; Pan J
Mol Cancer; 2019 Nov; 18(1):159. PubMed ID: 31718679
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
